Solid Tumor Cancers

Northwest Biotherapeutics has begun building its first Grade C manufacturing suite in the UK, aiming to significantly increase DCVax® production capacity. This transition, facilitated by their Flaskworks system, allows for simultaneous manufacturing of multiple patient products, improving efficiency compared to Grade B suites. The new suite is expected to be operational in Q2 next year. This expansion supports large-scale production of DCVax® personalized immune therapies, including DCVax-L for glioblastoma, for which the company has already submitted a Market Authorization Application in the UK.